It is known that more than 95% of the serum ALP activity is derived from hepatocytes and osteoblasts. Therefore, in patients with normal liver function, serum ALP seems available as the index of bone formation. Indeed, serum ALP as well as BAP levels were elevated in our case after bortezomib-combined therapy. Bisphosphonate has been reported as the potent inhibitor of osteoclastic activity and to reduce the skeletal complications in MM. 4 But our patient did not show the definite elevation of serum ALP levels after prior incadronate-containing salvage therapy, and the inability of bisphosphonate to repair lytic bone lesions indicates that the functional defect of osteoblasts is also important in the lytic process. 5 In this case, he showed the remarkable elevation of serum ALP as well as BAP levels after receiving bortezomib in combination with incadronate and dexamethasone. Our case suggested that bortezomib might have an effect on the osteoblastic activity in addition to antimyeloma activity. The possible mechanism is the rapid disappearance of myeloma cells induced by bortezomib. Myeloma cells secrete at least two molecules that modulate the bone microenvironment in a manner favorable to tumor growth. Receptor activator of NF-kB ligand (RANKL) acts to stimulate osteoclast formation and activity, leading to bone erosion, whereas dickkopf1 (DKK1) appears to inhibit osteoblasts by the Wnt signal pathway, thus preventing repair of the lesions.
It is known that more than 95% of the serum ALP activity is derived from hepatocytes and osteoblasts. Therefore, in patients with normal liver function, serum ALP seems available as the index of bone formation. Indeed, serum ALP as well as BAP levels were elevated in our case after bortezomib-combined therapy. Bisphosphonate has been reported as the potent inhibitor of osteoclastic activity and to reduce the skeletal complications in MM. 4 But our patient did not show the definite elevation of serum ALP levels after prior incadronate-containing salvage therapy, and the inability of bisphosphonate to repair lytic bone lesions indicates that the functional defect of osteoblasts is also important in the lytic process. 5 In this case, he showed the remarkable elevation of serum ALP as well as BAP levels after receiving bortezomib in combination with incadronate and dexamethasone. Our case suggested that bortezomib might have an effect on the osteoblastic activity in addition to antimyeloma activity. The possible mechanism is the rapid disappearance of myeloma cells induced by bortezomib. Myeloma cells secrete at least two molecules that modulate the bone microenvironment in a manner favorable to tumor growth. Receptor activator of NF-kB ligand (RANKL) acts to stimulate osteoclast formation and activity, leading to bone erosion, whereas dickkopf1 (DKK1) appears to inhibit osteoblasts by the Wnt signal pathway, thus preventing repair of the lesions. 5 Thus, removal of myeloma cells decreased the inhibition of DKK1 on canonical Wnt signal pathway, resulting in osteoblast differentiation. 6 Activation of canonical Wnt pathway induces ALP activity. 7 Another mechanism is that bortezomib directly inhibited the secretion of DKK1 from osteoblasts, which results in the activation of Wnt signal pathway and osteoblast differentiation. Recently, Oyajobi et al demonstrated that bortezomib inhibited DKK1 expression in cell lines of mesenchymal origin, and stimulated the new bone formation in neonatal mouse calvariae. 8 This case suggests the presence of new action of bortezomib on bone formation, and this effect might benefit the bone disease in patients with MM. Further studies are required to clarify this hypothesis. While testing the effect of Imatinib on BCR-ABL, c-KIT and PDGFR-negative cells gained from CLL patients in vitro we found that in certain cases Imatinib alone, applicated in clinically achievable concentrations of 0-20 mM, was able to induce apoptosis in these cells. However, the tested cells could clearly be segregated into 'responders' to Imatinib displaying regular dose-response curves and 'nonresponders', which were not affected by treatment with Imatinib. Similar results could be produced when testing cell lines of lymphatic origin such as DOHH-2, WSU-NHL, Karpas299, Raji, HUT78 and Jurkat, which are all deficient of the described Imatinib targets. The group could clearly be split into responders (DOHH-2, WSU-NHL, Karpas299) and nonresponders (Raji, HUT78, Jurkat). Apoptotic cell death was determined flowcytometrically with Annexin V/Propidium Iodide and cleavage of poly-(ADP-ribose)-polymerase (PARP) (Figure 1) .
By assessing the expression levels of c-Abl, the only possible known target left for Imatinib in the abscence of BCR-ABL, c-Kit and PDGFR, and its degree of phosphorylation as a marker for its activity 1 in the patient cells, we could show that the group of responders had higher levels of c-Abl and p-Abl as compared to the nonresponders. The levels of c-Abl and concomitantly p-Abl were strongly downregulated in the course of treatment after 48 h. In order to more clearly elucidate the underlying mechanisms of Imatinib-induced apoptosis in this context, we screened the expression levels of other apoptosis-associated proteins and found Prostate Apoptosis response gene 4 (Par-4) to be a further marker able to discriminate between responders and nonresponders. Par-4 was highly expressed in responders and almost not expressed in nonresponders (Figure 1 ). This is an interesting finding because the apoptosis-sensitizing protein Par-4 was shown to be able to abrogate the survival function and transforming capacity of BCR-ABL in transfected Ba/F3 and 32D cells 4 and was furthermore able to sensitize BCR-ABL-positive cells resistant to conventional cytotoxic drugs to treatment with Imatinib. 5 Since it was observed that proapoptotic effects of Par-4 might rely on downregulation of Bcl-2, we also assessed Bcl-2 expression in these samples; however, there was no lower Bcl-2 expression detectable in responders as compared to nonresponders ( Figure 1 ). Further analysis of the underlying apoptotic mechanisms induced by Imatinib in the responder cell lines showed that Imatinib-induced apoptosis relied on the activation of caspase-8 and -3 and led to concomitant PARP cleavage. Furthermore, similarly to the observation in the patient cells, Par-4 was downregulated in the course of treatment. As it was recently described by Kawai et al 6 that Par-4 might function in a novel apoptotic pathway in collaboration with Death associated protein (Daxx) and ZIP kinase in PML nuclear bodies, expression of these proteins was also tested: While Daxx was only highly expressed in DOHH-2 cells and remained uninfluenced by Imatinib treatment, ZIP kinase was present in all responder cell lines and, similar to Par-4 was downregulated in the course of incubation with Imatinib over 48 h. Of note, DOHH-2, the only responder cell line with high Daxx expression as compared to the others was also the most sensitive cell line to treatment with Imatinib, corroborating a possible proapoptotic collaboration of Par-4, ZIP kinase and Daxx. In the context of this pathway, a link might actually exist between manipulation of c-Abl kinase activity and Par-4: c-Abl was recently reported to selectively regulate p73 nuclear matrix association 7 while p73 in turn is an interaction Partner of Daxx in PML nuclear bodies 8 where it also interacts with Par-4 ( Figure 2 ). 6 In conclusion, these results support the notion that Imatinib applied in clinically achievable concentrations may sensitize Interestingly, it has been proposed that caspase-3 induction is involved in chlorambucil (CLB)-induced CLL lymphocytes apoptosis. 3 In this regard, the fact that we did not find a correlation between the CLB and STI571 IC 50 when used alone suggests that the mechanisms downstream of STI571 and CLBinduced apoptosis are not identical. 1 Thus, it will be informative to assess the involvement of Par-4 protein levels in CLB-induced apoptosis in primary CLL lymphocytes. If STI571 induces Par-4 while CLB does not, the mechanism of action proposed by Dr 
